MedTrace Logo

Extracorporeal Membrane Oxygenation (ECMO) and Coronavirus Disease (COVID) 19

NCT04397588 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 300

Last updated 2020-08-31

No results posted yet for this study

Summary

The role of ECMO in the treatment of patients with severe COVID-19 (Acute Respiratory Distress Syndrome (ARDS) and/or acute refractory heart failure) is not yet known. The present study will aim to report the results of the ECMO management of the most severe forms of COVID-19 through the first French ECMO registry.

Conditions

  • ARDS Related to Severe Acute Respiratory Syndrome-Coronavirus (SARS-CoV) 2
  • Acute Refractory Heart Failure Related to SARS-CoV 2

Sponsors & Collaborators

  • Rennes University Hospital

    lead OTHER

Principal Investigators

  • Nicolas Nesseler, doctor · Rennes University Hospital

  • André Vincentelli, professor · Lille University Hospital

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-04-21
Primary Completion
2020-10-21
Completion
2020-10-21

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04397588 on ClinicalTrials.gov